Heart failure & cardiomyopathiesSecondary analysis
Biomarker Profiles Associated with Reverse Ventricular Remodelling in Patients with Heart Failure and a Reduced Ejection Fraction: Insights from the Echocardiographic Substudy of the VICTORIA Trial
- Secondary analysis of the VICTORIA randomised trial
- echocardiographic substudy
- core-lab assessed echocardiograms
Authors' conclusion
Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) in the VICTORIA trial with paired echocardiograms and 92 biomarkers measured
- Participants
- 419 patients
- Comparison
- Reverse ventricular remodelling vs no reverse ventricular remodelling
- Reverse remodellingn = 206
- Primary endpoint
- Association of baseline biomarkers and their changes with reverse ventricular remodelling
- Follow-up
- 8 months
Primary result
As reported in the abstract
Reverse ventricular remodelling and biomarkers
Reverse remodelling
49.2%
206 of 206
- Tumour necrosis factor superfamily member 13B change with reverse remodelling, ratio
- 0.82 (95% CI 0.77-0.88)
- Growth differentiation factor-15 change with reverse remodelling, ratio
- 0.74 (95% CI 0.66-0.84)
- Insulin-like growth factor binding protein 7 change with reverse remodelling, ratio
- 0.80 (95% CI 0.73-0.88)
Original publication
Biomarker Profiles Associated with Reverse Ventricular Remodelling in Patients with Heart Failure and a Reduced Ejection Fraction: Insights from the Echocardiographic Substudy of the VICTORIA Trial. Eur J Heart Fail. Published 30 July 2024. doi:10.1002/ejhf.3397
Summarised from the published abstract; every number is checked against it